Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis
Aortic valve stenosis is the most common valvular heart disease in the Western world. Lipoprotein(a) (Lp(a)) is an independent risk factor of coronary heart disease (CHD) and calcific aortic valve stenosis (CAVS). The aim of this study was to assess the role of Lp(a) and its autoantibodies [autoAbs]...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Diseases |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-9721/11/1/43 |
| _version_ | 1827750255460876288 |
|---|---|
| author | Anna L. Burdeynaya Olga I. Afanasieva Marat V. Ezhov Elena A. Klesareva Marina A. Saidova Sergey N. Pokrovsky |
| author_facet | Anna L. Burdeynaya Olga I. Afanasieva Marat V. Ezhov Elena A. Klesareva Marina A. Saidova Sergey N. Pokrovsky |
| author_sort | Anna L. Burdeynaya |
| collection | DOAJ |
| description | Aortic valve stenosis is the most common valvular heart disease in the Western world. Lipoprotein(a) (Lp(a)) is an independent risk factor of coronary heart disease (CHD) and calcific aortic valve stenosis (CAVS). The aim of this study was to assess the role of Lp(a) and its autoantibodies [autoAbs] in CAVS in patients with and without CHD. We included 250 patients (mean age 69 ± 3 years, males 42%) and divided them into three groups. There were two groups of patients with CAVS depending on the presence (group 1) or absence of CHD (group 2). The control group included the patients without CHD or CAVS. According to logistic regression analysis, levels of Lp(a), IgM autoAbs to oxidized Lp(a) (oxLp(a)), and age were independent predictors of CAVS. A concomitant increase in Lp(a) level (≥30 mg/dL) and a decrease in IgM autoAbs concentration (<9.9 lab. Units) are associated with CAVS with an odds ratio (OR) of 6.4, <i>p</i> < 0.01, and with CAVS and CHD with an OR of 17.3, <i>p</i> < 0.001. IgM autoantibodies to oxLp(a) are associated with calcific aortic valve stenosis regardless of Lp(a) concentration and other risk factors. Higher Lp(a) and lower IgM autoantibodies to oxLp(a) levels are associated with a much higher risk of calcific aortic valve stenosis. |
| first_indexed | 2024-03-11T06:41:03Z |
| format | Article |
| id | doaj.art-9e93e85413bf457a9e3574e81399d99e |
| institution | Directory Open Access Journal |
| issn | 2079-9721 |
| language | English |
| last_indexed | 2024-03-11T06:41:03Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diseases |
| spelling | doaj.art-9e93e85413bf457a9e3574e81399d99e2023-11-17T10:36:44ZengMDPI AGDiseases2079-97212023-03-011114310.3390/diseases11010043Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve StenosisAnna L. Burdeynaya0Olga I. Afanasieva1Marat V. Ezhov2Elena A. Klesareva3Marina A. Saidova4Sergey N. Pokrovsky5Laboratory of Lipid Disorders, Department of Atherosclerosis, A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, RussiaLaboratory of Atherosclerosis, Institute of Experimental Cardiology Named after Academician V.N. Smirnov, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, RussiaLaboratory of Lipid Disorders, Department of Atherosclerosis, A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, RussiaLaboratory of Atherosclerosis, Institute of Experimental Cardiology Named after Academician V.N. Smirnov, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, RussiaDepartment of Ultrasound Diagnostics, A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, RussiaLaboratory of Atherosclerosis, Institute of Experimental Cardiology Named after Academician V.N. Smirnov, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, RussiaAortic valve stenosis is the most common valvular heart disease in the Western world. Lipoprotein(a) (Lp(a)) is an independent risk factor of coronary heart disease (CHD) and calcific aortic valve stenosis (CAVS). The aim of this study was to assess the role of Lp(a) and its autoantibodies [autoAbs] in CAVS in patients with and without CHD. We included 250 patients (mean age 69 ± 3 years, males 42%) and divided them into three groups. There were two groups of patients with CAVS depending on the presence (group 1) or absence of CHD (group 2). The control group included the patients without CHD or CAVS. According to logistic regression analysis, levels of Lp(a), IgM autoAbs to oxidized Lp(a) (oxLp(a)), and age were independent predictors of CAVS. A concomitant increase in Lp(a) level (≥30 mg/dL) and a decrease in IgM autoAbs concentration (<9.9 lab. Units) are associated with CAVS with an odds ratio (OR) of 6.4, <i>p</i> < 0.01, and with CAVS and CHD with an OR of 17.3, <i>p</i> < 0.001. IgM autoantibodies to oxLp(a) are associated with calcific aortic valve stenosis regardless of Lp(a) concentration and other risk factors. Higher Lp(a) and lower IgM autoantibodies to oxLp(a) levels are associated with a much higher risk of calcific aortic valve stenosis.https://www.mdpi.com/2079-9721/11/1/43calcific aortic valve stenosislipoprotein(a)autoantibodiescoronary heart disease |
| spellingShingle | Anna L. Burdeynaya Olga I. Afanasieva Marat V. Ezhov Elena A. Klesareva Marina A. Saidova Sergey N. Pokrovsky Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis Diseases calcific aortic valve stenosis lipoprotein(a) autoantibodies coronary heart disease |
| title | Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis |
| title_full | Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis |
| title_fullStr | Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis |
| title_full_unstemmed | Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis |
| title_short | Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis |
| title_sort | lipoprotein a and its autoantibodies in association with calcific aortic valve stenosis |
| topic | calcific aortic valve stenosis lipoprotein(a) autoantibodies coronary heart disease |
| url | https://www.mdpi.com/2079-9721/11/1/43 |
| work_keys_str_mv | AT annalburdeynaya lipoproteinaanditsautoantibodiesinassociationwithcalcificaorticvalvestenosis AT olgaiafanasieva lipoproteinaanditsautoantibodiesinassociationwithcalcificaorticvalvestenosis AT maratvezhov lipoproteinaanditsautoantibodiesinassociationwithcalcificaorticvalvestenosis AT elenaaklesareva lipoproteinaanditsautoantibodiesinassociationwithcalcificaorticvalvestenosis AT marinaasaidova lipoproteinaanditsautoantibodiesinassociationwithcalcificaorticvalvestenosis AT sergeynpokrovsky lipoproteinaanditsautoantibodiesinassociationwithcalcificaorticvalvestenosis |